XERS Q1 2023 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+50.4% YoY

Gross Profit

$28M84.0% margin

Operating Income

-$13M-40.0% margin

Net Income

-$17M-50.7% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+0.2%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$321M

Total Liabilities

$291M

Stockholders' Equity

$30M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$22M	+50.4%
Gross Profit	$28M	$16M	+76.4%
Operating Income	-$13M	-$29M	+54.3%
Net Income	-$17M	-$34M	+50.1%

Revenue Segments

Product

$32M72%

Keveyis

$13M28%